Cervical Spondylopathy
Conditions
Interventions
Control group:Oral celecoxib capsule + placebo acupuncture
Experimental group:Acupuncture + celecoxib placebot + health management
Sponsors
Dongzhimen Hospital Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18~70 years, male or female; 2. Meet the Western medical diagnostic standards for cervical spondylosis (Guidelines for the Diagnosis, Treatment and Rehabilitation of Cervical Spondylosis formulated by the Cervical Spondylosis Professional Committee of the Chinese Medicine Rehabilitation Association in 2010) and the Expert Consensus on the Classification, Diagnosis and Non-surgical Treatment of Cervical Spondylosis in 2018); 3. Meet the criteria for differentiation of Qi stasis and blood stasis in traditional Chinese medicine (the Standards for the Diagnosis and Efficacy of Traditional Chinese Medicine Diseases formulated by the State Administration of Traditional Chinese Medicine in 1994 and the Guidelines for Clinical Research of New Chinese Medicine formulated by the Ministry of Health of the People's Republic of China in 1995); 4. The patient or guardian agrees to participate in the research and signs an informed consent form to participate in the research. 5. Have the ability to complete the preoperative and postoperative questionnaire; 6. Normal liver and kidney function; 7. NRS score >= 3 points or above.
Exclusion criteria
Exclusion criteria: 1. Patients with severe abnormal functions of important organs such as heart, lung, liver, and kidney, and blood system; 2. Patients with moderate cognitive understanding or visual impairment who cannot cooperate with the completion of rehabilitation treatment and examination; 3. Women who are pregnant or breastfeeding at the same time; 4. Patients who are participating in other clinical studies. 5. Patients with local skin infection at acupuncture points. 6. Those who are allergic to sulfa drugs. 7. Those who are allergic to celecoxib. 8. Use of drugs that affect the observation of efficacy within 2 weeks before randomization. Include (any of the following): (1) taking aspirin or other nonsteroidal anti-inflammatory drugs; (2) External use of anti-inflammatory analgesia or blood activation and stasis plaster; (3) Patients who have done tuina, physiotherapy, and hot compress treatment; 9. Those with active gastrointestinal ulcer bleeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numerical rating scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Neck disability index;Changes in cervical curvature;Relapse rate; | — |
Countries
Chinese
Contacts
Public ContactSun Qi
Dongzhimen Hospital, Beijing University of Chinese Medicine
Outcome results
None listed